Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis.
OBJECTIVE
The incidence of diabetes mellitus is increased in patients with liver cirrhosis. Oltipraz is currently in trials to treat patients with liver fibrosis and cirrhosis induced by chronic hepatitis types B and C and is primarily metabolized via hepatic cytochrome P450 isozymes CYP1A1/2, 2B1/2, 2C11, 2D1 and 3A1/2 in rats. We have studied the influence of diabetes mellitus on pharmacokinetics of oltipraz and on expression of hepatic, CYP1A, 2B1/2, 2C11, 2D and 3A in rats with experimental liver cirrhosis.


METHODS
Oltipraz was given intravenously (10 mg x kg(-1)) or orally (30 mg x kg(-1)) to rats with liver cirrhosis induced by N-dimethylnitrosamine (LC rats) or with diabetes, induced by streptozotocin (DM rats) or to rats with both liver cirrhosis and diabetes (LCD rats) and to control rats, and pharmacokinetic variables measured. Protein expression of hepatic CYP1A, 2B1/2, 2C11, 2D and 3A was measured using Western blot analysis.


RESULTS
After i.v. or p.o. administration of oltipraz to LC and DM rats, the AUC was significantly greater and smaller, respectively, than that in control rats. In LCD rats, the AUC was that of LC and DM rats (partially restored towards control rats). Compared with control rats, the protein expression of hepatic CYP1A increased, that of CYP2C11 and 3A decreased, but that of CYP2B1/2 and 2D was not altered in LCD rats.


CONCLUSIONS
In rats with diabetes and liver cirrhosis, the AUC of oltipraz was partially restored towards that of control rats.
Ahn
C Y
CY
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea.
Bae
S K
SK
Bae
S H
SH
Kim
T
T
Jung
Y S
YS
Kim
Y C
YC
Lee
M G
MG
Shin
W G
WG
D000818:Animals; D019540:Area Under Curve; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism*; D008099:Liver / Q000201:enzymology; D008106:Liver Cirrhosis, Experimental / Q000150:complications / Q000378:metabolism*; D011719:Pyrazines / Q000493:pharmacokinetics*; D051381:Rats; D012556:Schistosomicides / Q000493:pharmacokinetics*; D013871:Thiones; D013876:Thiophenes
D011719:Pyrazines; D012556:Schistosomicides; D013871:Thiones; D013876:Thiophenes; C026209:oltipraz; D003577:Cytochrome P-450 Enzyme System